dna-dollars-150px.gifLast year was a tough one for IPOs, as Matt noted earlier, and so far this year looks even worse. Aptamer-drug maker Archemix today became the third life-science startup this month to withdraw or postpone an IPO, and the sixth so far this year. We take a closer look at the worsening IPO climate and the contrast with still-bullish venture funding in the sector, over at VentureBeat Life Sciences.

Tags: , ,
Trackback URL

  1. Life sciences briefing: Monday, Feb. 18, 2008 » VentureBeat said:

    [...] infusion services, dropped its proposed $125 million IPO. The withdrawal isn’t related to the broader slump in health-related IPOs, which has claimed eight proposed offerings so far this year, as Critical Healthcare agreed last [...]